EUVIMEDEUVIMED entdecken
Scoping Review

A scoping review of breakthrough cancer pain: mapping the evidence landscape

Mellar Davis, Russell Portenoy, Andrew Davies, Sebastiano Mercadante, Akhila Reddy, M R Rajagopal, Eduardo Bruera

Supportive Care in Cancer · 2026-04 · 34 (4)

DOI: 10.1007/s00520-026-10506-3 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Supportive Care in Cancer, online erschienen am 07.03.2026. Verfasst von Mellar Davis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Supportive Oncology, Levine Cancer Institute, Charlotte, NC, USA. Mellar.Davis@advocatehealth.org. Hauptthemen laut MEDLINE: Breakthrough Pain, Cancer Pain, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Breakthrough pain (BTP) in cancer populations is characterized by heterogeneous definitions, assessment approaches, and management strategies. This scoping review mapped the available evidence to characterize BTP concepts, describe the evidence base, and identify knowledge gaps. METHODS: Following JBI methodology and PRISMA-ScR guidelines, we searched PubMed, Embase, Scopus, Cochrane Library, Web of Science, and Google Scholar for studies published January 1991-June 2025. Included studies employed quantitative designs investigating BTP definition, assessment, characteristics, or pharmacological management in adult cancer patients. BTP was defined conceptually as transient pain exacerbation occurring with controlled background pain; studies using varying operational criteria were included and categorized to examine definitional heterogeneity. Data were extracted by one reviewer using a piloted form and synthesized narratively with stratification by era, definition category, population, and intervention type. Consistent with scoping review standards, formal quality appraisal was not conducted; this review maps evidence without assessing strength or making recommendations. RESULTS: 146 studies (33 RCTs with 3,471 participants; 113 observational studies with 9,841 participants) were included. While 90% endorsed BTP as transient severe pain on controlled background pain, operational definitions varied substantially regarding pain intensity thresholds (range: no threshold to ≤ 4/10 background, ≥ 7/10 episode), opioid requirements (61% required regular opioids), and temporal criteria (12% specified duration limits). BTP characteristics showed marked heterogeneity: onset seconds to 30 min, duration 3-240 min, frequency 1 to > 10 episodes daily. Prevalence estimates ranged 33-95%, associated with definitional variation. Clinical trials predominantly evaluated transmucosal fentanyl using enriched enrollment (excluding 15-28% non-responders) and focused on pain intensity at 15-30 min. Industry sponsored 82% of trials. Evidence concentrated in resource-rich settings; minimal data from resource-limited regions. CONCLUSIONS: This scoping review maps heterogeneous evidence characterized by inconsistent definitions, selected populations, short-term outcomes, and geographic concentration. Key knowledge gaps include: standardized operational definitions, patient-centered functional outcomes, long-term efficacy and safety data, evidence from diverse settings and populations, and integration of pharmacological and non-pharmacological approaches. The review provides a descriptive landscape but does not assess evidence quality or support treatment recommendations. Future guidance development requires expert consensus processes incorporating mapped evidence, clinical experience, resource availability, and patient values. Addressing identified gaps through rigorous, pragmatic research will strengthen the evidence base for BTP management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breakthrough PainCancer PainNeoplasmsHumansAnalgesics, OpioidPain MeasurementPain ManagementEvidence Gaps

Stichwörter der Autor:innen

Breakthrough painCancer painEpisodic painEvidence synthesisKnowledge gapsScoping review

Substanzen

Analgesics, Opioid

Autor:innen und Institutionen

  • Department of Supportive Oncology, Levine Cancer Institute, Charlotte, NC, USA. Mellar.Davis@advocatehealth.org.
  • Department of Family and Social Medicine, Albert Einstein College of Medicine, New York, NY, USA.
  • Trinity College Dublin, University College Dublin, Our Lady's Hospice Care Services, Dublin 4, Ireland.
  • Main Regional Center for Pain Relief and Palliative Care, La Maddalena Cancer Center, Palermo, Italy.
  • Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pallium India Trust, Aisha Memorial Hospital Building, Paruthikuzhy, India.

Zitieren

APA

Davis, M., Portenoy, R., Davies, A., Mercadante, S., Reddy, A., Rajagopal, M. R., & Bruera, E. (2026). A scoping review of breakthrough cancer pain: mapping the evidence landscape. Supportive Care in Cancer, 34(4). https://doi.org/10.1007/s00520-026-10506-3

Vancouver

Davis M, Portenoy R, Davies A, Mercadante S, Reddy A, Rajagopal MR, et al. A scoping review of breakthrough cancer pain: mapping the evidence landscape. Supportive Care in Cancer. 2026;34(4). doi:10.1007/s00520-026-10506-3

BibTeX
@article{Davis2026,
  author = {Davis, Mellar and Portenoy, Russell and Davies, Andrew and Mercadante, Sebastiano and Reddy, Akhila and Rajagopal, M R and Bruera, Eduardo},
  title = {A scoping review of breakthrough cancer pain: mapping the evidence landscape},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {4},
  doi = {10.1007/s00520-026-10506-3}
}
Kostenlos starten →